NASDAQ:GANX

Gain Therapeutics (GANX) Stock Price, News & Analysis

Gain Therapeutics logo
$1.05 -0.06 (-5.41%)
Closing price 11/19/2026 04:00 PM Eastern
Extended Trading
$1.11 +0.06 (+5.62%)
As of 11/19/2026 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Gain Therapeutics Stock (NASDAQ:GANX)

Advanced

Key Stats

Today's Range
$1.03
▼
$1.14
50-Day Range
$0.94
▼
$1.95
52-Week Range
$0.94
▼
$4.34
Volume
552,856 shs
Average Volume
761,411 shs
Market Capitalization
$46.76 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.67
Consensus Rating
Moderate Buy

Company Overview

Gain Therapeutics, Inc. is a biotechnology company developing small-molecule treatments for neurological and other diseases linked to dysfunctional proteins. Its research focuses on conditions for which existing therapies may not address the underlying protein dysfunction.

The company uses its discovery platform, which combines computational methods and structural biology, to identify previously unexplored binding sites on proteins. It aims to develop compounds that bind at these sites and help restore protein function.

Gain Therapeutics’ lead program, GT-02287, is an oral investigational therapy being developed for Parkinson’s disease, including disease associated with GBA1 mutations. The company is also pursuing drug-discovery programs for other neurological and lysosomal disorders.

AI Generated. May Contain Errors.

Gain Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
46th Percentile Overall Score

GANX MarketRank™: 
2.28814723252 of 5 stars

Gain Therapeutics scored higher than 46% of companies evaluated by MarketBeat, and ranked 533rd out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Gain Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on no strong buy ratings, 4 buy ratings, no hold ratings, and 1 sell rating.

  • Upside Potential

    Gain Therapeutics has a consensus price target of $7.67, representing about 630.2% upside from its current price of $1.05.

  • Amount of Analyst Coverage

    Gain Therapeutics has only been the subject of 3 research reports in the past 90 days.

  • Read more about Gain Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Gain Therapeutics are expected to decrease in the coming year, from ($0.43) to ($0.47) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Gain Therapeutics is -2.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Gain Therapeutics is -2.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Gain Therapeutics has a P/B Ratio of 4.57. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    9.30% of the float of Gain Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Gain Therapeutics has a short interest ratio ("days to cover") of 5.55.
  • Change versus previous month

    Short interest in Gain Therapeutics has recently increased by 21.93%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Gain Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Gain Therapeutics does not have a long track record of dividend growth.

  • News Sentiment

    Gain Therapeutics has a news sentiment score of 1.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.39 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 10 news articles for Gain Therapeutics this week, compared to 2 articles on an average week.
  • Search Interest

    1 people have searched for GANX on MarketBeat in the last 30 days.
  • MarketBeat Follows

    4 people have added Gain Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Gain Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    4.15% of the stock of Gain Therapeutics is held by insiders.

  • Percentage Held by Institutions

    11.97% of the stock of Gain Therapeutics is held by institutions.

  • Read more about Gain Therapeutics' insider trading history.
Receive GANX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Gain Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

GANX Stock News Headlines

URGENT: If you own a home, please review the map below.
More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards urges homeowners to check the map and see whether one is near them. Families in Georgia have been forced to sell, entire Ohio neighborhoods are being torn down, and nearly 50,000 Lake Tahoe residents face losing power. Rickards advised the Pentagon and the U.S. intelligence community for decades. He says one man outside Washington can stop it.tc pixel
HC Wainwright Lifts Earnings Estimates for Gain Therapeutics
Gain Therapeutics Q3 Loss Narrows
Gain Therapeutics (GANX) Projected to Announce Earnings on Wednesday
See More Headlines

GANX Stock Analysis - Frequently Asked Questions

Gain Therapeutics' stock was trading at $3.22 at the start of the year. Since then, GANX shares have decreased by 67.4% and is now trading at $1.05.

Gain Therapeutics, Inc. (NASDAQ:GANX) released its earnings results on Tuesday, November, 10th. The company reported ($0.07) earnings per share for the quarter, beating analysts' consensus estimates of ($0.12) by $0.05.

Gain Therapeutics (GANX) raised $40 million in an IPO on Thursday, March 18th 2021. The company issued 3,636,364 shares at a price of $10.00-$12.00 per share. BTIG and Oppenheimer & Co,. acted as the underwriters for the IPO and National Securities Corp. was co-manager.

Gain Therapeutics' top institutional shareholders include Marshall Wace LLP (3.77%), Hohimer Wealth Management LLC (0.76%), State Street Corp (0.46%) and Empowered Funds LLC (0.12%). Insiders that own company stock include Eric I Richman, Khalid Islam, Jeffrey Scott Riley, Gene Mack and Matthias Alder.
View institutional ownership trends
.

Shares of GANX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Gain Therapeutics investors own include NVIDIA (NVDA), Tonix Pharmaceuticals (TNXP), IonQ (IONQ), Pfizer (PFE), Immunic (IMUX), Iovance Biotherapeutics (IOVA) and Aclaris Therapeutics (ACRS).

Company Calendar

Last Earnings
11/10/2026
Today
11/19/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:GANX
CIK
1819411
Fax
N/A
Employees
21
Year Founded
2017

Price Target and Rating

High Price Target
$10.00
Low Price Target
$5.00
Potential Upside/Downside
+630.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.60
Research Coverage
5 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.42)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$20.16 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-133.17%
Return on Assets
-102.45%

Debt

Debt-to-Equity Ratio
0.02
Current Ratio
5.36
Quick Ratio
5.36

Sales & Book Value

Annual Sales
$50 thousand
Price / Sales
935.13
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.23 per share
Price / Book
4.57

Miscellaneous

Outstanding Shares
44,530,000
Free Float
42,677,000
Market Cap
$46.76 million
Optionable
Optionable
Beta
0.29

Social Links

10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

This page (NASDAQ:GANX) was last updated on 11/19/2026 by MarketBeat.com Staff.
From Our Partners